Can bisphosphonates improve outcomes in patients with newly diagnosed multiple myeloma?

Critical Reviews in Oncology/Hematology

Volumn 77, Issue SUPPL.1, 2011, Pages

  Morgan, Gareth J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Anticancer; Antimyeloma; Bisphosphonate; Clodronate; Myeloma; Skeletal related event; Survival; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CLODRONIC ACID; CREATININE; DEXAMETHASONE; ETIDRONIC ACID; IBANDRONIC ACID; ISOPENTENYL DIPHOSPHATE; MELPHALAN; PAMIDRONIC ACID; PLACEBO; PREDNISONE; THALIDOMIDE; ZOLEDRONIC ACID;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE ATROPHY; BONE CANCER; BONE DESTRUCTION; BONE METASTASIS; CANCER SURVIVAL; CREATININE BLOOD LEVEL; DRUG EFFICACY; EVENT FREE SURVIVAL; HIGH RISK PATIENT; HUMAN; IMMUNOMODULATION; JAW OSTEONECROSIS; KIDNEY DYSFUNCTION; MULTIPLE MYELOMA; NONHUMAN; OSTEOCLAST; OVERALL SURVIVAL; PATHOLOGIC FRACTURE; PLASMACYTOMA; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; VERTEBRA FRACTURE;

ANIMALS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; CLODRONIC ACID; DIPHOSPHONATES; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; IMIDAZOLES; MALE; MICE; MULTIPLE MYELOMA; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISK FACTORS; TREATMENT OUTCOME;

EID: 79951843681     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(11)70005-1     Document Type: Review

References (42)

1. World Health Organization International Agency for Research on Cancer. GLOBOCAN 2008 [accessed November 5, 2010]. http://globocan.iarc.fr/.
2. Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc 2009, 84:1095-1110.
3. Kyle RA, Rajkumar SV Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009, 23:3-9.
4. Coleman RE Metastatic bone disease: clinical features, patho-physiology and treatment strategies. Cancer Treat Rev 2001, 27:165-176.
5. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC Multiple myeloma. Lancet 2009, 374:324-339.
6. Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K, Libermann TA, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappaB. Blood 1996, 87:1104-1112.
7. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC Advances in biology of multiple myeloma: clinical applications. Blood 2004, 104:607-618.
8. Kuehl WM, Bergsagel PL Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002, 2:175-187.
9. Terpos E, Dimopoulos MA, Berenson J Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease. Crit Rev Oncol Hematol 2011, 77(1):S13-S23.
10. Baulch-Brown C, Molloy TJ, Yeh SL, Ma D, Spencer A Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma. Leuk Res 2007, 31:341-352.
11. Shipman CM, Rogers MJ, Apperley JF, Russell RG, Croucher PI Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol 1997, 98:665-672.
12. Tassone P, Forciniti S, Galea E, Morrone G, Turco MC, Martinelli Y, et al. Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia 2000, 14:841-844.
13. Ural AU, Yilmaz MI, Aveu F, Pekel A, Zerman M, Nevruz O, et al. The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide. Int J Hematol 2003, 78:443-449.
14. Corso A, Ferretti E, Lunghi M, Zappasodi P, Mangiacavalli S, De Amici M, et al. Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect. Cancer 2005, 104:118-125.
15. Zwolak P, Manivel JC, Jasinski P, Kirstein MN, Dudek AZ, Fisher J, et al. Cytotoxic effect of zoledronic acid-loaded bone cement on giant cell tumor, multiple myeloma, and renal cell carcinoma cell lines. J Bone Joint Surg Am 2010, 92:162-168.
16. Schmidmaier R, Simsek M, Baumann P, Emmerich B, Meinhardt G Synergistic antimyeloma effects of zoledronate and simvastatin. Anticancer Drugs 2006, 17:621-629.
17. Koizumi M, Nakaseko C, Ohwada C, Takeuchi M, Ozawa S, Shimizu N, et al. Zoledronate has an antitumor effect and induces actin rearrangement in dexamethasone-resistant myeloma cells. Eur J Haematol 2007, 79:382-391.
18. Uchida R, Ashihara E, Sato K, Kimura S, Kuroda J, Takeuchi M, et al. Gamma delta T cells kill myeloma cells by sensing mevalonate metabolites and ICAM-1 molecules on cell surface. Biochem Biophys Res Commun 2007, 354:613-618.
19. Kunzmann Y, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000, 96:384-392.
20. Moschetta M, Di Pietro G, Ria R, Gnoni A, Mangialardi G, Guarini A, et al. Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma. Eur J Cancer 2010, 46:420-429.
21. Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 2002, 116:278-290.
22. Croucher PI, De Hendrik R, Perry MJ, Hijzen A, Shipman CM, Lippitt J, et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 2003, 18:482-492.
23. Guenther A, Gordon S, Tiemann M, Burger R, Bakker F, Green JR, et al. The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation. Int J Cancer 2010, 126:239-246.
24. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009, 360:679-691.
25. Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Poestlberger S, Dubsky PC, et al. Mature results from ABCSG-12: adjuvant ovarian suppression combined with tamoxifen or anastro-zole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer. J Clin Oncol 2010, 28(Suppl):75s. [abstract 533].
26. Dearnaley DP, Mason MD, Parmar MK, Sanders K, Sydes MR Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol 2009, 10:872-876.
27. Aviles A, Nambo MJ, Neri N, Castaneda C, Cleto S, Huerta-Guzman J Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol 2007, 24:227-230.
28. Berenson J, Dimopoulos M, Chen Y-M. Improved survival in patients with multiple myeloma and high BALP levels treated with zoledronic acid compared with pamidronate: univariate and multivariate models of hazard ratios. Presented at 48th ASH Annual Meeting and Exposition, 2006 [abstract 3589].
29. McCloskey EV, Dunn JA, Kanis JA, MacLennan IC, Drayson MT Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol 2001, 113:1035-1043.
30. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 1998, 16:593-602.
31. Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010, 376:1989-1999.
32. Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Drayson MT, et al. Optimising bone disease in myeloma; zoledronic acid plus thalidomide combinations improve survival and bone endpoints: results of the Myeloma IX trial. Presented at 52nd ASH Annual Meeting and Exposition, 2010 [abstract 311].
33. Zometa (zoledronic acid) injection [package insert] 2008, Novartis Pharmaceuticals Corporation, East Hanover, NJ.
34. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008, 23:826-836.
35. Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007, 110:1860-1867.
36. UK-Nordic Guidelines Working Group UK Myeloma Forum and the Nordic Myeloma Study Group: Guidelines on the Diagnosis and Management of Multiple Myeloma 2005 [accessed November 5, 2010]. http://www.bcshguidelines.com/documents/multiplemyeloma_feb_2006.pdf.
37. Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Comenzo RL, et al. Multiple myeloma. Clinical practice guidelines in oncology. J Natl Compr Cane Netw 2007, 5:118-147.
38. Harrouseau JL, Greil R, Kloke O ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of multiple myeloma. Ann Oncol 2005, 16(Suppl l):i45-i47.
39. Kyle RA, Yee GC, Somerfield MR, Flynn PJ, Halabi S, Jagannath S, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007, 25:2464-2472.
40. Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR, et al. Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 2006, 81:1047-1053.
41. Brufsky AM, Bosserman LD, Caradonna RR, Haley BB, Jones CM, Moore HC, et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 2009, 9:77-85.
42. Mhaskar R, Redzepovic J, Wheatley K, Clark O, Glasmacher A, Miladinovic B, et al. Comparative effectiveness of bisphosphonates in multiple myeloma. Presented at 52nd ASH Annual Meeting and Exposition, 2010 [abstract 3028].